Navigation Links
Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced results regarding the efficacy and safety of ORENCIA(R) (abatacept) from the open-label phase of an ongoing investigational study in children with juvenile idiopathic arthritis (JIA) who have had an inadequate response to one or more disease-modifying anti- rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. The results demonstrated that, after a study protocol- mandated withdrawal period of up to six months, the re-introduction of ORENCIA was associated with a re-establishment of clinical improvement as measured by the of Rheumatology's Pediatric (ACR Pedi) criteria for improvement in children with JIA. The data will be presented tomorrow at the Annual Congress of the European League Against Rheumatism.

"Children with JIA can have long periods of inactive disease and clinical remission, which makes it important to study the efficacy and safety of re- starting a treatment after a withdrawal period," said Edward H. Giannini, M.Sc., Dr.P.H., Professor of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, OH, co-principal investigator of the study. "The results of this investigational study suggest that, in these children with JIA who had disease flares while taking placebo during the mandated withdrawal phase, resuming therapy with ORENCIA was associated with a re-establishment of clinical improvement."

The study, designed to assess the efficacy, safety and tolerability of ORENCIA in children and adolescents (ages 6-17 years) with JIA, consisted of three periods: a four-month open-label lead-in treatment period in which all participants received ORENCIA and both a clinical response and safety were assessed (Period A), a six-month randomized double-blind withdrawal phase where responders received either ORENCIA(R) (abatac
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia

Post Your Comments:
(Date:11/6/2009)...Mass., Nov. 6 Facet Solutions, Inc...assets of Archus Orthopedics. The acquisition crea...fferings, intellectual property and clinical exper... win for patients suffering from lumbar spinal ste...O, Geoff Pardo. "This consolidation further stren...
(Date:11/6/2009)...anitoba, Nov. 6 With his proposed ...s set his sights on cutting name-brand prescriptio...ho fall into the "Part D" coverage gap, universall...bout the potential cost-cutting and feel it,s a pr...he most powerful lobbyists want a revised program ...
(Date:11/6/2009)...v. 6 GeoVax Labs, Inc. ...any"), an Atlanta-based, biopharmaceutical company...HIV-1 (Human Immunodeficiency Virus) and other inf...2009 financial results and provided an operational...d Chief Executive Officer commented, "We are pleas...
Breaking Medicine Technology:Facet Solutions Acquires Archus Orthopedics 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8ReBuilder Medical Technologies Inc Announces First Quarter 2009 is Profitable 55336 1ReBuilder Medical Technologies Inc Announces First Quarter 2009 is Profitable 55336 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 1Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 3Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 4Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 5Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 6Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 7Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 8HPV Vaccine Could Prevent Many Penile Cancers 55330 1HPV Vaccine Could Prevent Many Penile Cancers 55330 2
...(TM) HBSAG Test Found to Have Higher Sensitivity a...FirstVue(TM) ,...and was the preferred ... SPRINGS, Fla., Oct. 13 AT First Diagnostic LLC a...gnostic test kits, today,announced that a recent e...ute of Research of the FirstVue(TM) HBSAG Test, wa...
...n of Genomic DNA from Multiple Cancer Populations ...dies, ANN ARBOR, Mich., Oct. 13 Rubicon Genomics...erick to amplify DNA samples for The,Cancer Atlas ... amplify and standardize total genomic,DNA from 3,... The Rubicon,GenomePlex(TM) Whole Genome Amplifica...
Other Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3
(Date:11/9/2009)... Leading U.S. air ambulance company no...EURAMI accreditation and Department of Defense app...PRWEB) November 9, 2009 -- AirMed International, t...oday it has earned full accreditation from the Eur...a Stuttgart, Germany, based non-profit association...
(Date:11/9/2009)...K, Nov. 9 Davis Bregman , a pai...e calls to residents of Manhattan in New York City... by calling the office at 212-918-1629 or sendin...ence of being able to see the doctor in the less s... this new way of seeing most patients. The servic...
(Date:11/8/2009)...TON, Nov. 8 Jon O,Brien...llowing statement about the passage of HR 3962: ,...erican voters a lot about core values. We in the p... seeking to overcome the struggles ordinary Americ...at many cannot afford basic healthcare or have to ...
(Date:11/8/2009)... UCW Academy of Health holds open hous...ctoria, BC (Vocus) November 8, 2009 -- UCW Academy...r in British Columbia’s health care industry...ay, November 25, 2009. , ,UCW Academy of Health, ...ion, nursing and social services, designs its prog...
(Date:11/8/2009)... New book called "Preventing and ...r. Roberto Giraldo shows that AIDS is a result of ...ty of so-called immune system stressor agents, whi...nd most of all, emotional. , ...Nov. 6 – 8, 2009, cell biologists, physician...
Breaking Medicine News(10 mins):Health News:AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation 2Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3
... The more overweight children are, the poorer qual...ing to a new study.// Nearly 2,000 children par...th-related quality of life using a short survey co...he children studied were not overweight; about 20 ...
... A new study shows a clear link between fast food ..., suggesting that // fast food increases the risk ...estigated the association between reported fast fo... that changes in fast food frequency over 15 years...
... A new study shows men who consume three or more a...stroke. An ischemic stroke develops // when an art... Researchers studied more than 38,000 participan...mic stroke among the study participants. Results o...
... Moderate physical exercise can significantly redu... heart disease in older adults //, say researchers...revious cardiovascular disease, between ages 55 an...ics. The other half only received a booklet encour...
... The wet form of macular degeneration represents a... Age-related macular degeneration is the leading c... 50 years of age and older. // Two new studies sho...centers in the United States, Canada, Europe, Isra...
... High blood sugar, or hyperglycemia, is a common p...f whether they are diabetic or not.// The conditio...insulin resistance, impaired glucose metabolism, v...nvestigated more than 1,800 consecutive patients a...
Other Medicine News:
Pefakit TDT
Pefakit PiCT Controls LMWH
Pefakit TAFI Calibrator/Control
QuikCoag Control 3
Medicine Products: